Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amivantamab - Genmab/Janssen Biotech

Next Previous
X
Search
Drug Profile

Amivantamab - Genmab/Janssen Biotech

Alternative Names: Ami-LC-MD; Amivantamab admixed with rHuPH20; Amivantamab-vmjw; Bispecific EGFR-cMet antibody; CNTO4424; EGFR-MET bispecific antibody; EGFRxcMET bispecific antibody; JNJ 372; JNJ-61186372; JNJ-6372; RYBREVANT

Latest Information Update: 27 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Janssen Biotech
  • Developer Janssen Biotech; Janssen Research & Development; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Gastric cancer; Liver cancer; Oesophageal cancer
  • Phase I/II Colorectal cancer; Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 27 Sep 2024 Launched for Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 19 Sep 2024 Registered for Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 19 Sep 2024 Updated efficacy and adverse events data from the phase III MARIPOSA-2 trial in Non-small cell lung cancer released by Johnson & Johnson

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top